Clinical Trial Update: Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating carfilzomib with daratumumab, lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma patients has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Tel-Aviv Sourasky Medical Center | Conditions: Myeloma Multiple, Myeloma, Plasma-Cell | Phase 2 | Status: COMPLETED